Over the past couple of years, patients with retinal damage have been filing lawsuits against the makers of Elmiron (pentosan polysulfate sodium), the only drug approved to treat interstitial cystitis. The judge overseeing the Elmiron multidistrict litigation (MDL), which is housed in the United States District Court for the District of New Jersey, will hold a “Science Day” to hear presentations from both sides of the litigation. 

The plaintiffs with claims filed in the MDL are awaiting the next steps in the litigation, with trials to begin in 2022. The main defendants at issue in the Elmiron litigation include Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson Pharmaceuticals, Inc.), Teva Branded Pharmaceutical Products R&D, Inc., and Teva Pharmaceuticals USA, Inc.

What is a “Science Day?” Our Elmiron Lawyer Explains 

A Science Day is a common occurrence in MDLs involving pharmaceutical drugs and medical devices. Pharmaceutical drug cases can be complicated. Both the attorneys and judges must understand the medicine and data behind the drug at issue in mass tort litigation. Judges often order Science Days, which provides attorneys for plaintiffs and defendants with an opportunity to present evidence and expert testimony to support their claims or defenses.

In most pharmaceutical MDLs, sufficient evidence exists to move forward with claims. Judges cannot rule on matters pertaining to litigation without first fully understanding the science behind the drug and injuries at issue. Science Days are meant to be more informative, providing judges with a snapshot of the strength of the evidence that supports plaintiffs’ claims.

Interstitial Cystitis and Elmiron

Interstitial cystitis (IC) is a painful bladder condition that affects millions of patients, with most patients being women. For decades, patients have taken Elmiron (pentosan polysulfate sodium) to treat IC, with no other alternative to treat the condition. In recent years, studies have revealed a link between the use of Elmiron and retinal damage

One study published in October of 2019 by the American Academy of Ophthalmology indicates that approximately twenty-five percent of patients with “significant” exposure to Elmiron developed conditions resulting in retinal damage, such as pattern dystrophy (which includes a group of retinal conditions) and age-related macular degeneration (also known as maculopathy).

A January 2020 article published by the Journal of the Canadian Urological Association identifies multiple studies that support a link between long-term usage of Elmiron and the development of macular degeneration and other retinal conditions. Although Elmiron has been used for decades, data has only recently come to light. Patients who have relied on Elmiron to treat a painful bladder condition now run the risk of developing a retinal condition, which has the potential to lead to central vision loss.

Contact Searcy Denney Today for a Free Consultation

Have you been diagnosed with macular degeneration or any other retinal condition after taking Elmiron? If you have taken Elmiron for at least two years prior to your eye damage diagnosis, consider reaching out to an Elmiron lawyer who can evaluate your situation to determine whether you have a potential legal claim. 

At Searcy Denney, our dangerous drug lawyers understand the complicated science behind pharmaceutical mass tort litigations, and the Elmiron litigation is no exception. To schedule a free consultation to discuss your potential Elmiron claim, contact our office today by calling (800) 780-8607 or by completing a free case evaluation form on our website.

The post Court to Hold “Science Day” in Elmiron Retinal Damage MDL appeared first on Searcy Law.